Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
DBV Technologies S.A is a biotechnology business based in the US. DBV Technologies S-A shares (DBVT) are listed on the NASDAQ and all prices are listed in US Dollars. DBV Technologies S-A employs 97 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.37|
|52-week range||$1.35 - $6.94|
|50-day moving average||$5.12|
|200-day moving average||$5.52|
|Wall St. target price||$11.05|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.19|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||10.49%|
|1 month (2021-09-21)||7.62%|
|3 months (2021-07-21)||4.07%|
|6 months (2021-04-21)||-12.68%|
|1 year (2020-10-21)||253.29%|
|2 years (2019-10-21)||-28.02%|
|3 years (2018-10-19)||18.91|
|5 years (2016-10-21)||35.57|
|Revenue TTM||$4.4 million|
|Gross profit TTM||$11.3 million|
|Return on assets TTM||-29.85%|
|Return on equity TTM||-66.03%|
|Market capitalisation||$589.1 million|
TTM: trailing 12 months
There are currently 1.1 million DBV Technologies S-A shares held short by investors – that's known as DBV Technologies S-A's "short interest". This figure is 1.4% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting DBV Technologies S-A shares can be evaluated.
DBV Technologies S-A's "short interest ratio" (SIR) is the quantity of DBV Technologies S-A shares currently shorted divided by the average quantity of DBV Technologies S-A shares traded daily (recently around 57891.607629428). DBV Technologies S-A's SIR currently stands at 18.35. In other words for every 100,000 DBV Technologies S-A shares traded daily on the market, roughly 18350 shares are currently held short.
However DBV Technologies S-A's short interest can also be evaluated against the total number of DBV Technologies S-A shares, or, against the total number of tradable DBV Technologies S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DBV Technologies S-A's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DBV Technologies S-A shares in existence, roughly 10 shares are currently held short) or 0.0174% of the tradable shares (for every 100,000 tradable DBV Technologies S-A shares, roughly 17 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against DBV Technologies S-A.
Find out more about how you can short DBV Technologies S-A stock.
We're not expecting DBV Technologies S-A to pay a dividend over the next 12 months.
Over the last 12 months, DBV Technologies S-A's shares have ranged in value from as little as $1.35 up to $6.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DBV Technologies S-A's is 2.2521. This would suggest that DBV Technologies S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.
DBV Technologies S. A. , a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.